Publikasi Scopus 2010 s/d 2022

Sato K., White N., Fanning J.P., Obonyo N., Yamashita M.H., Appadurai V., Ciullo A., May M., Worku E.T., Helms L., Ohshimo S., Juzar D.A., Suen J.Y., Bassi G.L., Fraser J.F., Arora R.C., Dalton H.J., Laffey J., Brodie D., Fan E., Torres A., Chiumello D., Elhazmi A., Hodgson C., Ichiba S., Luna C., Murthy S., Nichol A., Ng P.Y., Ogino M., Marwali E., Yang I., Dip G., Grasselli G., Bartlett R., Burrell A., COVID-19 Critical Care Consortium Investigators
57216496603;55441104800;53983925400;20735366100;36629635200;55634491600;56278087300;21834310200;57218324688;57544863600;15731705200;55358712500;35081233700;13611676700;34769608400;7202894376;7103262112;26643063000;8333064800;7006443489;57205521091;55200445900;57222475716;57189236566;56637110400;57214546627;36247670800;25645294900;57889089300;57739257400;36608535400;58114682000;57200782513;36904573700;57662960300;56457901900;
Impact of renin–angiotensin–aldosterone system inhibition on mortality in critically ill COVID-19 patients with pre-existing hypertension: a prospective cohort study
2022
BMC Cardiovascular Disorders
22
1
123
3
Critical Care Research Group, The Prince Charles Hospital, Level 3, Clinical Sciences Building, Chermside, Brisbane, QLD 4032, Australia; Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia; Australian Centre for Health Services Innovation (AusHSI) and Centre for Healthcare Transformation, Queensland University of Technology (QUT), Brisbane, QLD, Australia; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Wellcome Trust Centre for Global Health Research, Imperial College London, London, United Kingdom; Initiative to Develop African Research Leaders/KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya; Section of Cardiac Surgery, Department of Surgery, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB, Canada; Department of Cardiology, The Prince Charles Hospital, Brisbane, QLD, Australia; Division of Emergency Medicine, Department of Surgery, University of Utah Health, Salt Lake City, UT 84132, United States; Department of Microbiology, Sullivan Nicolaides Pathology, Brisbane, QLD, Australia; Adult Intensive Care Services, The Prince Charles Hospital, Brisbane, QLD, Australia; Department of Emergency and Critical Care Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan; Intensive Cardiovascular Care Unit, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia; Division Intensive & Emergency Cardiovascular Care, Department Cardiology and Vascular Medicine, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Institut d’Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain
Sato, K., Critical Care Research Group, The Prince Charles Hospital, Level 3, Clinical Sciences Building, Chermside, Brisbane, QLD 4032, Australia, Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia; White, N., Australian Centre for Health Services Innovation (AusHSI) and Centre for Healthcare Transformation, Queensland University of Technology (QUT), Brisbane, QLD, Australia; Fanning, J.P., Critical Care Research Group, The Prince Charles Hospital, Level 3, Clinical Sciences Building, Chermside, Brisbane, QLD 4032, Australia, Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Obonyo, N., Critical Care Research Group, The Prince Charles Hospital, Level 3, Clinical Sciences Building, Chermside, Brisbane, QLD 4032, Australia, Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia, Wellcome Trust Centre for Global Health Research, Imperial College London, London, United Kingdom, Initiative to Develop African Research Leaders/KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya; Yamashita, M.H., Section of Cardiac Surgery, Department of Surgery, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB, Canada; Appadurai, V., Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia, Department of Cardiology, The Prince Charles Hospital, Brisbane, QLD, Australia; Ciullo, A., Division of Emergency Medicine, Department of Surgery, University of Utah Health, Salt Lake City, UT 84132, United States; May, M., Department of Microbiology, Sullivan Nicolaides Pathology, Brisbane, QLD, Australia; Worku, E.T., Adult Intensive Care Services, The Prince Charles Hospital, Brisbane, QLD, Australia; Helms, L., Critical Care Research Group, The Prince Charles Hospital, Level 3, Clinical Sciences Building, Chermside, Brisbane, QLD 4032, Australia; Ohshimo, S., Department of Emergency and Critical Care Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan; Juzar, D.A., Intensive Cardiovascular Care Unit, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia, Division Intensive & Emergency Cardiovascular Care, Department Cardiology and Vascular Medicine, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Suen, J.Y., Critical Care Research Group, The Prince Charles Hospital, Level 3, Clinical Sciences Building, Chermside, Brisbane, QLD 4032, Australia, Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia; Bassi, G.L., Critical Care Research Group, The Prince Charles Hospital, Level 3, Clinical Sciences Building, Chermside, Brisbane, QLD 4032, Australia, Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia, Institut d’Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain; Fraser, J.F., Critical Care Research Group, The Prince Charles Hospital, Level 3, Clinical Sciences Building, Chermside, Brisbane, QLD 4032, Australia, Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia, Adult Intensive Care Services, The Prince Charles Hospital, Brisbane, QLD, Australia; Arora, R.C., Section of Cardiac Surgery, Department of Surgery, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB, Canada; Dalton, H.J.; Laffey, J.; Brodie, D.; Fan, E.; Torres, A.; Chiumello, D.; Elhazmi, A.; Hodgson, C.; Ichiba, S.; Luna, C.; Murthy, S.; Nichol, A.; Ng, P.Y.; Ogino, M.; Marwali, E.; Yang, I.; Dip, G.; Grasselli, G.; Bartlett, R.; Burrell, A.; COVID-19 Critical Care Consortium Investigators
Background: The influence of renin–angiotensin–aldosterone system (RAAS) inhibitors on the critically ill COVID-19 patients with pre-existing hypertension remains uncertain. This study examined the impact of previous use of angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) on the critically ill COVID-19 patients. Methods: Data from an international, prospective, observational cohort study involving 354 hospitals spanning 54 countries were included. A cohort of 737 COVID-19 patients with pre-existing hypertension admitted to intensive care units (ICUs) in 2020 were targeted. Multi-state survival analysis was performed to evaluate in-hospital mortality and hospital length of stay up to 90 days following ICU admission. Results: A total of 737 patients were included—538 (73%) with pre-existing hypertension had received ACEi/ARBs before ICU admission, while 199 (27%) had not. Cox proportional hazards model showed that previous ACEi/ARB use was associated with a decreased hazard of in-hospital death (HR, 0.74, 95% CI 0.58–0.94). Sensitivity analysis adjusted for propensity scores showed similar results for hazards of death. The average length of hospital stay was longer in ACEi/ARB group with 21.2 days (95% CI 19.7–22.8 days) in ICU and 6.7 days (5.9–7.6 days) in general ward compared to non-ACEi/ARB group with 16.2 days (14.1–18.6 days) and 6.4 days (5.1–7.9 days), respectively. When analysed separately, results for ACEi or ARB patient groups were similar for both death and discharge. Conclusions: In critically ill COVID-19 patients with comorbid hypertension, use of ACEi/ARBs prior to ICU admission was associated with a reduced risk of in-hospital mortality following adjustment for baseline characteristics although patients with ACEi/ARB showed longer length of hospital stay. Clinical trial registration The registration number: ACTRN12620000421932; The date of registration: 30, March 2020; The URL of the registration: https://www.australianclinicaltrials.gov.au/anzctr/trial/ACTRN12620000421932. © 2022, The Author(s).
Angiotensin receptor blockers; Angiotensin-converting enzyme inhibitors; COVID-19; Critical care; Severe acute respiratory syndrome coronavirus 2
angiotensin receptor antagonist; dipeptidyl carboxypeptidase inhibitor; cohort analysis; critical illness; hospital mortality; human; hypertension; prospective study; renin angiotensin aldosterone system; retrospective study; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cohort Studies; COVID-19; Critical Illness; Hospital Mortality; Humans; Hypertension; Prospective Studies; Renin-Angiotensin System; Retrospective Studies
School of Medicine; National University of Ireland; Wellcome Trust; University of Manitoba; Health Research Board; “la Caixa” Foundation; Wesley Medical Research; Vagelos College of Physicians and Surgeons, Columbia University; European Commission; Monash University; Queensland University of Technology; University of Queensland; Hiroshima University; University of Hong Kong; University of British Columbia; Universidad de Buenos Aires; Universitas Indonesia; Horizon 2020; Fondazione IRCCS Ca' Gra
This study received discretionary funding from University of Queensland, Wesley Medical Research, The Prince Charles Hospital Foundation, The Health Research Board of Ireland, Biomedicine international training research programme for excellent clinician-scientists, European Union’s research and innovation programme (Horizon 2020), and la Caixa Foundation. All of them have not and will not have any
We appreciate all collaborative organizations including ISARIC/SPRINT-SARI and all investigators (Additional file 1 : Document S2) who registered patients’ data on behalf of the COVID-19 Critical Care Consortium. COVID-19 Critical Care Consortium Investig
BioMed Central Ltd
14712261
35321649
Article
Q2
675
7176